Imugene is a publicly-listed biotechnology company with operations in America and Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.

ASX: IMU

Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies.

Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our PD-1 B-cell vaccine, known as KEY-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies, that have transformed treatment for a range of cancers. KEY-Vaxx has shown encouraging potential in preclinical studies, including outperforming an industry-standard mouse anti-PD-1 antibody in a mouse model of HER2+ colorectal cancer.

Imugene has two HER2 B-cell vaccines in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both vaccines showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell vaccine technology as well as suggesting therapeutic potential in HER2+ cancers.

  See  our Clinical Pipeline

See our Clinical Pipeline

  Read  our latest ASX news

Read our latest ASX news

  Download  our latest Fact Sheet

Download our latest Fact Sheet

  Watch  CEO Leslie Chong’s latest interview

Watch CEO Leslie Chong’s latest interview